Construction of the plasmid for expression of ETA-EGFP fusion protein under control of the cytomegalovirus promoter and its effects in HeLa cells

Plasmid

Volumn 62, Issue 2, 2009, Pages 119-127

  Glinka, Elena M ^a   Andryushchenko, Alla S ^a   Sapozhnikov, Alexander M ^a   Zatsepina, Olga V ^a  

^a SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

Author keywords

Apoptosis; Fusion protein; Inhibition; Nucleolar protein; Pseudomonas exotoxin A; Redistribution

Indexed keywords

CASPASE 3; ENHANCED GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; NUCLEAR PROTEIN; NUCLEOLAR ANTIGEN A3; PSEUDOMONAS EXOTOXIN; PSEUDOMONAS EXOTOXIN A; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CONTROLLED STUDY; CYTOMEGALOVIRUS; DOWN REGULATION; EXPRESSION VECTOR; GENE EXPRESSION REGULATION; HELA CELL; HUMAN; HUMAN CELL; NONHUMAN; PLASMID; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS INHIBITION; SUICIDE GENE THERAPY; TRANSIENT TRANSFECTION; TRANSLATION REGULATION;

ADP RIBOSE TRANSFERASES; BACTERIAL TOXINS; CYTOMEGALOVIRUS; EXOTOXINS; GENE EXPRESSION; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HELA CELLS; HUMANS; PLASMIDS; PROMOTER REGIONS, GENETIC; TRANSFECTION; VIRULENCE FACTORS;

CYTOMEGALOVIRUS; EUKARYOTA; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS EXOTOXIN;

EID: 67650729307     PISSN: 0147619X     EISSN: 10959890     Source Type: Journal    
DOI: 10.1016/j.plasmid.2009.06.004     Document Type: Article

References (26)

1. Abdul-Ghani R., Ohana P., Matouk I., Ayesh S., Ayesh B., Laster M., Bibi J., Giladi H., Molnar-Kimber K., Sughayer M.A., de Groot N., and Hochberg A. Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells. Mol. Ther. 2 (2000) 539-544
2. Cemazar M., Sersa G., Wilson J., Tozer G.M., Hart S.L., Grosel A., and Dachs G.U. Effective gene transfer to solid tumors using different nonviral gene delivery techniques: electroporation, liposomes, and integrin-targeted vector. Cancer Gene Ther. 9 (2002) 399-406
3. Chan P.K. Characterization and cellular localization of nucleophosmin/B23 in HeLa cells treated with selected cytotoxic agents (studies of B23-translocation mechanism). Exp. Cell Res. 203 (1992) 174-181
4. Denis-Mize K.S., Price B.M., Baker N.R., and Galloway D.R. Analysis of immunization with DNA encoding Pseudomonas aeruginosa exotoxin A. FEMS Immunol. Med. Microbiol. 27 (2000) 147-154
5. FitzGerald D.J., Willingham M.C., and Pastan I. Pseudomonas exotoxin-immunotoxins. Int. J. Mol. Med. 15 (2005) 305-313
6. Goto T., Nishi T., Tamura T., Dev S.B., Takeshima H., Kochi M., Yoshizato K., Kuratsu J., Sakata T., Hofmann G.A., and Ushio Y. Highly efficient electro-gene therapy of solid tumor by using an expression plasmid for the herpes simplex virus thymidine kinase gene. Proc. Natl. Acad. Sci. USA 97 (2000) 354-359
7. Grigoryev A.A., Bulycheva T.I., Sheval E.V., Kalinina I.A., and Zatsepina O.V. Cytological indicators of the overall suppression of protein synthesis revealed by staining with new monoclonal antibody. Cell Tissue Biol. 2 (2008) 191-199
8. Gu J., Zhang L., Huang X., Lin T., Yin M., Xu K., Ji L., Roth J.A., and Fang B. A novel single tetracycline-regulative adenoviral vector for tumor-specific Bax gene expression and cell killing in vitro and in vivo. Oncogene 21 (2002) 4757-4764
9. Hafkemeyer P., Brinkmann U., Gottesman M.M., and Pastan I. Apoptosis induced by Pseudomonas exotoxin: a sensitive and rapid marker for gene delivery in vivo. Hum. Gene Ther. 10 (1999) 923-934
10. Jenkins C.E., Swiatoniowski A., Issekutz A.C., and Lin T.J. Pseudomonas aeruginosa exotoxin A induces human mast cell apoptosis by a caspase-8 and -3-dependent mechanism. J. Biol. Chem. 279 (2004) 37201-37207
11. Keppler-Hafkemeyer A., Kreitman R.J., and Pastan I. Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies. Int. J. Cancer 87 (2000) 86-94
12. Kimchi-Sarfaty C., Vieira W.D., Dodds D., Sherman A., Kreitman R.J., Shinar S., and Gottesman M.M. SV40 Pseudovirion gene delivery of a toxin to treat human adenocarcinomas in mice. Cancer Gene Ther. 13 (2006) 648-657
13. Krajewska M., Wang H.-G., Krajewski S., Zapata J.M., Shabaik A., Gascoyne R., and Reed J.C. Immunohistochemical analysis of in vivo patterns of expression of CPP32 (caspase-3), a cell death protease. Cancer Res. 57 (1997) 1605-1613
14. Kreitman R.J., Squires D.R., Stetler-Stevenson M., Noel P., FitzGerald D.J., Wilson W.H., and Pastan I. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J. Clin. Oncol. 23 (2005) 6719-6729
15. Kunitomi M., Takayama E., Suzuki S., Yasuda T., Tsutsui K., Nagaike K., Hiroi S., and Tadakuma T. Selective inhibition of hepatoma cells using diphtheria toxin A under the control of the promoter/enhancer region of the human alpha-fetoprotein gene. Jpn. J. Cancer Res. 91 (2000) 343-350
16. Li Y., McCadden J., Ferrer F., Kruszewski M., Carducci M., Simons J., and Rodriguez R. Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer. Cancer Res. 62 (2002) 2576-2582
17. Lidor Y.J., Lee W.E., Nilson J.H., Maxwell I.H., Su L.J., Brand E., and Glode L.M. In vitro expression of the diphtheria toxin A-chain gene under the control of human chorionic gonadotropin gene promoters as a means of directing toxicity to ovarian cancer cell lines. Am. J. Obstet. Gynecol. 177 (1997) 579-585
18. Lo H.W., Day C.P., and Hung M.C. Cancer-specific gene therapy. Adv. Genet. 54 (2005) 235-255
19. Lopez M.V., Blanco P., Viale D.L., Cafferata E.G., Carbone C., Gould D., Chernajovsky Y., and Podhajcer O.L. Expression of a suicidal gene under control of the human secreted protein acidic and rich in cysteine (SPARC) promoter in tumor or stromal cells led to the inhibition of tumor cell growth. Mol. Cancer Ther. 5 (2006) 2503-2511
20. Martín V., Cortés M.L., de Felipe P., Farsetti A., Calcaterra N.B., and Izquierdo M. Cancer gene therapy by thyroid hormone-mediated expression of toxin genes. Cancer Res. 60 (2000) 3218-3224
21. Rainov N.G., and Söling A. Clinical studies with targeted toxins in malignant glioma. Rev. Recent Clin. Trials 1 (2006) 119-131
22. Robson T., and Hirst D.G. Transcriptional targeting in cancer gene therapy. J. Biomed. Biotechnol. 2003 (2003) 110-137
23. von Minckwitz G., Harder S., Hövelmann S., Jäger E., Al-Batran S.E., Loibl S., Atmaca A., Cimpoiasu C., Neumann A., Abera A., Knuth A., Kaufmann M., Jäger D., Maurer A.B., and Wels W.S. Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. Breast Cancer Res. 7 (2005) R617-R626
24. Wels W., Harwerth I.M., Mueller M., Groner B., and Hynes N.E. Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res. 52 (1992) 6310-6317
25. Wels W., Biburger M., Müller T., Dälken B., Giesübel U., Tonn T., and Uherek C. Recombinant immunotoxins and retargeted killer cells: employing engineered antibody fragments for tumor-specific targeting of cytotoxic effectors. Cancer Immunol. Immunother. 53 (2004) 217-226
26. Yung B.Y., Bor A.M., and Chan P.K. Short exposure to actinomycin D induces reversible translocation of protein B23 as well as "reversible" inhibition of cell growth and RNA synthesis in HeLa cells. Cancer Res. 50 (1990) 5987-5991